Epidemiology and Management of Cutaneous T-Cell Lymphoma at Hospital México, Costa Rica.

Epidemiological Profile and Therapeutic Management of Patients Diagnosed With Cutaneous T-cell Lymphoma Evaluated in the Dermatology Department of Hospital México During the Period From 2019 to 2025.

Adult patients (≥18 years) with confirmed cutaneous T-cell lymphoma evaluated at Hospital México between 2019 and 2025 will be retrospectively analyzed using EDUS records to describe their epidemiological profile, clinical characteristics, treatments, and outcomes.

Study Overview

• Status: Not yet recruiting
• Conditions: T-cell Lymphoma; Cutaneous; Lymph Node Cancer

Detailed Description

This retrospective observational study will analyze adult patients (≥18 years) with a confirmed diagnosis of cutaneous T-cell lymphoma evaluated in the Dermatology Service of Hospital México between January 2019 and December 2025. Data will be obtained from electronic medical records (EDUS), including sociodemographic characteristics, clinical presentation, histopathological and immunohistochemical findings, disease staging, treatment modalities, and clinical outcomes.

Patients must have at least one documented dermatological evaluation and have received treatment, including skin-directed therapies and/or systemic therapies. Records that are incomplete, inconsistent, or lack histopathological confirmation will be excluded.

The study aims to characterize local epidemiological and therapeutic patterns and describe clinical outcomes using descriptive statistical analysis, providing updated real-world evidence to support clinical decision-making and optimize management strategies for cutaneous T-cell lymphoma in a national referral center.

• Study Type: Observational
• Enrollment (Estimated): 350

Contacts and Locations

• Study Contact: Name: Daniel Barquero-Orias, Dermatologist; Phone Number: +506 83411026; Email: debarque@ccss.sa.cr

Study Locations

• Costa Rica
  • Uruca
    • San José, Uruca, Costa Rica, 10107
      • Hospital México
      • Contact: Daniel Barquero-Orias, Dermatologist; Phone Number: +506 83411026; Email: debarque@ccss.sa.cr
      • Principal Investigator: Raquel Ramirez-Fallas, Dermatology Resident
      • Sub-Investigator: Said Fallas-Moya, Dermatologist
      • Sub-Investigator: Daniel Barquero-Orias, Dermatologist

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

he study population will consist of adult patients (≥18 years) of both sexes with a confirmed diagnosis of cutaneous T-cell lymphoma, established through clinical, histopathological, and immunohistochemical criteria, and documented in EDUS at the Dermatology Service of Hospital México between January 2019 and December 2025. Patients must have at least one recorded dermatological evaluation during the study period and must have received some form of treatment, including skin-directed therapies (phototherapy, topical treatments, localized radiotherapy) and/or systemic therapies.

Patients with insufficient or incomplete clinical records that prevent adequate diagnostic classification, staging, therapeutic characterization, or evaluation of clinical evolution will be excluded, as well as those with a presumptive diagnosis without histopathological confirmation, duplicate or inconsistent records, patients attended outside the study period, those outside the defined age range, and patients.

Description

Inclusion Criteria:

• Patients with a confirmed diagnosis of cutaneous T-cell lymphoma, established through clinical, histopathological, and immunohistochemical criteria, documented in EDUS of Hospital México in the Dermatology Service of Hospital México during the period between January 2019 and December 2025.
• Patients aged 18 years or older, of both sexes.
• Patients with at least one dermatological evaluation recorded during the study period.
• Patients who, having a confirmed diagnosis, have received some modality of treatment, including skin-directed therapies (phototherapy, topical treatments, localized radiotherapy) and/or systemic treatments.

Exclusion Criteria:

• Clinical records that are insufficient or incomplete, preventing adequate diagnostic classification, staging, therapeutic characterization, or evaluation of clinical evolution.
• Patients with a presumptive diagnosis of cutaneous T-cell lymphoma without histopathological confirmation.
• Duplicate or inconsistent records that hinder the correct identification and classification of the patient.
• Patients attended outside the established study period.
• Patients outside the age range.
• Patients who do not belong to the Dermatology Service of Hospital México.

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Characterize the epidemiology	Characterize the epidemiology of patients diagnosed with cutaneous T-cell lymphoma evaluated in the Dermatology Service of Hospital México.	2019-2025
Characterize the therapeutic management	Characterize the therapeutic management of patients diagnosed with cutaneous T-cell lymphoma evaluated in the Dermatology Service of Hospital México	2019-2025.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Describe the sociodemographic/epidemiological characteristics	To describe the sociodemographic and epidemiological characteristics of patients diagnosed with cutaneous T-cell lymphoma evaluated in the Dermatology Service of Hospital México during the period from 2019 to 2025.	2019-2025
Classify the clinical manifestations/clinical subtypes	Classify the clinical manifestations and clinical subtypes of cutaneous T-cell lymphoma present in the studied population.	2019-2025
Identify the histopathological/ immunohistochemical findings	To identify the histopathological and immunohistochemical findings associated with cutaneous T-cell lymphoma in the included patients.	2019-2025
Analyze the therapeutic management modalities.	Analyze the therapeutic management modalities used, including skin-directed therapies and their outcomes.	2019-2025
identify the clinical stage at the time of diagnosis	identify the clinical stage of the disease at the time of diagnosis according to the TNMB staging system.	2019-2025
Evaluation of imaging studies and laboratory.	Evaluate imaging studies and laboratory findings of patients with cutaneous T-cell lymphoma during the follow-up period.	2019-2025
Evaluation of clinical course and outcomes.	Evaluation of clinical course and outcomes of patients with cutaneous T-cell lymphoma during the follow-up period.	2019-2025

Collaborators and Investigators

• Sponsor: Caja Costarricense de Seguro Social

Study record dates

Study Major Dates

• Study Start (Estimated): May 1, 2026
• Primary Completion (Estimated): May 1, 2027
• Study Completion (Estimated): May 1, 2027

Study Registration Dates

• First Submitted: April 11, 2026
• First Submitted That Met QC Criteria: April 13, 2026
• First Posted (Actual): April 20, 2026

Study Record Updates

• Last Update Posted (Actual): April 20, 2026
• Last Update Submitted That Met QC Criteria: April 13, 2026
• Last Verified: April 1, 2026

More Information

Terms related to this study

• Keywords: Therapy; T-Cell Lymphoma; Cutaneous Lymphoma; Linfoma
• Additional Relevant MeSH Terms: Neoplasms; Immune System Diseases; Neoplasms by Histologic Type; Lymphatic Diseases; Lymphoproliferative Disorders; Immunoproliferative Disorders; Lymphoma, Non-Hodgkin; Lymphoma; Hemic and Lymphatic Diseases; Lymphoma, T-Cell; Lymphoma, T-Cell, Cutaneous
• Other Study ID Numbers: CEC HM 002-2026

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: According to protocol

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No